Glaxo Smith Kline

Type
Internal restructuring
Country
United Kingdom
Region
North West (England); Cumbria; Westmorland and Furness
Location of affected unit(s)
Ulverston
Sector
Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
330 jobs
Number of planned job losses
Job loss
Announcement Date
22 February 2008
Employment effect (start)
22 February 2008
Foreseen end date
28 February 2010

Description

Pharmaceutical company GlaxoSmithKline has announced that it is to cut 330 jobs from its Ulverston factory over the next 2 years. The company cited the loss of patents on some products, the increasing costs of the site and its lack of competitiveness as reasons for the job cuts. It stated that the cuts were needed to ensure that the site remained competitive in the future. The trade union at the site UNITE are engaged in talks with management. They have said that it is a body blow to the local economy where no comparable manufacturing jobs are available.

Sources

  • 22 February 2008: BBC Website

Citation

Eurofound (2008), Glaxo Smith Kline, Internal restructuring in United Kingdom, factsheet number 66331, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/66331.